The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting maintenance of hepatitis B virus DNA to its lowest possible level. The threshold of hepatitis B virus DNA level for therapy is ≥105 copies/mL for HBeAg-positive patients and ≥104 for those with HBeAg-negative chronic hepatitis B. Interferon alpha-2b, lamivudine, and adefovir-dipivoxil are approved by FDA and could all be used as an initial first-line therapy in chronic hepatitis B. Adding lamivudine to either conventional interferon or peg-interferon did not increase the efficacy. Adding lamivudine to adefovir had also no additional effect in compensated patients. Response rate is about 30 % – 40 % with first-line drugs. Peg-interferon, which r...
International audienceThe treatment of chronic hepatitis B is now based on the using of pegylated in...
Session: Chronic Liver Failure - Clinical AspectsThis book is proceedings of Falk Symposium 174, Aug...
Treatment is considered for patients with high HBV DNA, elevated ALT levels and evidence of inflamma...
There has been a recent paradigm shift in the indications and endpoints of treatment for chronic hep...
This review updates the treatment of chronic hepatitis B infection. Complete eradication of hepatiti...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Three hundred and fifty million people worldwide are estimated to be chronically infected with hepat...
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to ...
Three agents have been approved for the treatment of chronic hepatitis B virus (HBV): interferon-alp...
In the past decade, physicians treating chronic hepatitis Bhave gained the luxury of choice. The U.S...
A durable suppression of viral replication in chronic HBV infection decreases the risk of liver dise...
Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrh...
Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation and ...
Chronic hepatitis B (CHB) is one of the important public health problems worldwide. Major advances h...
Effective antiviral therapy for chronic hepatitis B virus (HBV) infection is important since ∼400 mi...
International audienceThe treatment of chronic hepatitis B is now based on the using of pegylated in...
Session: Chronic Liver Failure - Clinical AspectsThis book is proceedings of Falk Symposium 174, Aug...
Treatment is considered for patients with high HBV DNA, elevated ALT levels and evidence of inflamma...
There has been a recent paradigm shift in the indications and endpoints of treatment for chronic hep...
This review updates the treatment of chronic hepatitis B infection. Complete eradication of hepatiti...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Three hundred and fifty million people worldwide are estimated to be chronically infected with hepat...
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to ...
Three agents have been approved for the treatment of chronic hepatitis B virus (HBV): interferon-alp...
In the past decade, physicians treating chronic hepatitis Bhave gained the luxury of choice. The U.S...
A durable suppression of viral replication in chronic HBV infection decreases the risk of liver dise...
Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrh...
Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation and ...
Chronic hepatitis B (CHB) is one of the important public health problems worldwide. Major advances h...
Effective antiviral therapy for chronic hepatitis B virus (HBV) infection is important since ∼400 mi...
International audienceThe treatment of chronic hepatitis B is now based on the using of pegylated in...
Session: Chronic Liver Failure - Clinical AspectsThis book is proceedings of Falk Symposium 174, Aug...
Treatment is considered for patients with high HBV DNA, elevated ALT levels and evidence of inflamma...